Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00767767 · ClinicalTrials.gov registry record · NA
The Effect of Intravenous Anesthetics on Fear Learning and Memory
A NA study, sponsored by Weill Medical College of Cornell University.
- Completed
- Registry status
- NA
- Development phase
- 67
- Enrollment target
NCT00767767: Completed NA study, sponsored by Weill Medical College of Cornell University.
NCT00767767 is a NA study that has completed, run by Weill Medical College of Cornell University. The registered enrollment target is 67 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00767767, a NA study, has completed, sponsored by Weill Medical College of Cornell University.
- COMPLETED
- Registry status
- NA
- Development phase
- 67 participants
- Enrollment target
Study Summary
People often develop fearful responses to things, but have no conscious control over the fear. This is a basic form of unconscious memory, called "fear conditioning." Intravenous anesthetic drugs have remarkable effects on conscious memory, but it is unknown whether they have similar effects on these unconscious fear memories. To address this question, the investigators will study 114 healthy adult volunteer subjects. The subject is given a very low dose of an anesthetic drug intravenously (i.e. through the bloodstream). The dose is so low that the subject might not even be able tell if they are getting the drug. While they are receiving the drug, the subject will perform a series of memory tests and a fear conditioning experiment, which are set up like a very simple computer game. To create the "fear response", subjects will occasionally receive a mildly uncomfortable shock to their arm. The subject is able to determine the highest level of shock that they will receive. The investigators are doing this study because the investigators wish to know exactly how the drugs affect the way people process fear and emotion. This knowledge might one day be used in the treatment of some psychiatric disorders.
Primary Outcome
Galvanic skin repose (GSR) to the first habituation trial (yes/no). Coding: Yes (0) and No (1)
Interventions
- DRUG Placebos
- DRUG Propofol 0.45mcg/mL
- DRUG Propofol 0.90mcg/mL
- DRUG Thiopental 1.5mcg/mL
- DRUG Thiopental 3mcg/mL
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 67 participants |
| Start Date | 2008-10 |
| Est. Completion | 2011-05 |
| Phase | NA |
What the finished NCT00767767 record still lists
NCT00767767 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 67 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 5 interventions - of which Placebos is the first listed.
NCT00767767 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00767767 about?
NCT00767767 is a clinical study titled "The Effect of Intravenous Anesthetics on Fear Learning and Memory". People often develop fearful responses to things, but have no conscious control over the fear. This is a basic form of unconscious memory, called "fear conditioning." Intravenous anesthetic drugs have remarkable effects on conscious memory, but it is unknown whether they have similar effects on thes...
What is the current status of trial NCT00767767?
This trial is currently completed. It is a NA study. The enrollment target is 67 participants. The study started on 2008-10. Estimated completion is 2011-05.
What interventions are being tested in trial NCT00767767?
The interventions under investigation include: Placebos (DRUG), Propofol 0.45mcg/mL (DRUG), Propofol 0.90mcg/mL (DRUG), Thiopental 1.5mcg/mL (DRUG), Thiopental 3mcg/mL (DRUG).
Who is sponsoring clinical trial NCT00767767?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00767767's enrollment target sits among peer trials
67 1139th of 2000 higher than 862 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03213002 · 67 participants · Phase 1
Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM
- NCT04115163 · 67 participants · Phase 2
Biologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer
- NCT04315324 · 67 participants · Phase 1
Study to Test OBI-3424 in Patients With T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LBL)
- NCT04532424 · 67 participants · NA
Transcranial Magnetic Stimulation for Restricted and Repetitive Behavior in ASD
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia